Organon & Co. (OGN) to Release Earnings on Thursday

Organon & Co. (NYSE:OGN - Get Free Report) is projected to release its Q4 2024 earnings data before the market opens on Thursday, February 13th. Analysts expect Organon & Co. to post earnings of $0.92 per share and revenue of $1.59 billion for the quarter. Organon & Co. has set its FY 2025 guidance at EPS.Persons interested in registering for the company's earnings conference call can do so using this link.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. On average, analysts expect Organon & Co. to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Organon & Co. Stock Down 6.3 %

NYSE:OGN traded down $1.03 during trading hours on Friday, hitting $15.30. The company's stock had a trading volume of 4,424,393 shares, compared to its average volume of 2,825,816. The stock has a market capitalization of $3.94 billion, a P/E ratio of 3.03, a price-to-earnings-growth ratio of 0.83 and a beta of 0.76. The stock has a fifty day moving average of $15.35 and a 200-day moving average of $17.48. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. Organon & Co. has a 52-week low of $13.87 and a 52-week high of $23.10.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 13th. Investors of record on Monday, February 24th will be issued a $0.28 dividend. This represents a $1.12 annualized dividend and a yield of 7.32%. The ex-dividend date of this dividend is Monday, February 24th. Organon & Co.'s dividend payout ratio (DPR) is presently 22.22%.

Analysts Set New Price Targets

Several research firms recently commented on OGN. Morgan Stanley dropped their target price on Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating on the stock in a report on Friday. Barclays dropped their target price on Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a report on Friday. Finally, TD Cowen upgraded shares of Organon & Co. to a "hold" rating in a research note on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, two have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Organon & Co. currently has an average rating of "Hold" and a consensus target price of $20.80.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.